Back to Search
Start Over
AMBRA1 and FAK1: crosstalking for improved targeted therapy in melanoma.
- Source :
-
Molecular & Cellular Oncology . 2021, Vol. 8 Issue 4, p1-3. 3p. - Publication Year :
- 2021
-
Abstract
- Through genetically engineered mouse models of melanoma, we identified Autophagy/beclin 1 regulator 1 (Ambra1) as novel tumor-suppressor in melanoma. In these settings, loss of Ambra1 associated with the hyperactivation of focal adhesion kinase 1 (Fak1) signaling, the inhibition of which resulted in reduced tumor growth and invasiveness. We therefore propose FAK1 inhibition for current melanoma therapy in AMBRA1-low tumors. AKT, serine/threonine kinase 1; AMBRA1, autophagy/beclin 1 regulator 1; BRAF, v-raf murine sarcoma viral oncogene homolog; BRAFi, BRAF inhibitor; CCLE, Cancer Cell Line Encyclopedia;g ESTDAB, European Searchable Tumor Line Database; FAK1, focal adhesion kinase 1; FAKi, FAK1 inhibitor; LMC, Leeds Melanoma Cohort; MEK, MAPK/ERK kinase; PP2A, protein phosphatase 2A; PTEN, phosphatase and tensin homolog; TCGA-SKCM, The Cancer Genome Atlas - Skin Cutaneous Melanoma; YAP, yes-associated protein 1. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 23723556
- Volume :
- 8
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Molecular & Cellular Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 152789013
- Full Text :
- https://doi.org/10.1080/23723556.2021.1949955